-
-
-
-
-
-
-
Takeda's zasocitinib beats deucravacitinib in psoriasis study
-
-
-
-
-
-
-
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
-
-
-
-
-
-
-
FDA accepts Takeda drug application for narcolepsy treatment
-
-
-
-
-
-
-
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
-
-
-
-
-
-
-
Takeda reports 7-year dengue vaccine data showing sustained protection
-
-
-
-
-
-
-
Takeda partners with VELA for wind-powered pharmaceutical shipping
-
-
-
-
-
-
-
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
-
1,171,485 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

